Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Cencora ( (COR) ) is now available.
On August 6, 2025, Cencora announced its fiscal third-quarter results for 2025, reporting an 8.7% increase in revenue to $80.7 billion compared to the previous year. The company’s GAAP diluted EPS rose to $3.52, while adjusted diluted EPS increased to $4.00, leading to an upward revision of its fiscal 2025 EPS guidance. The growth was attributed to strategic acquisitions and a focus on digital transformation, talent investment, and productivity, enhancing its position as a preferred partner in the healthcare sector.
The most recent analyst rating on (COR) stock is a Buy with a $250.00 price target. To see the full list of analyst forecasts on Cencora stock, see the COR Stock Forecast page.
Spark’s Take on COR Stock
According to Spark, TipRanks’ AI Analyst, COR is a Outperform.
Cencora’s strong financial performance and positive earnings outlook are key strengths, despite high leverage and valuation concerns. Recent corporate events enhance liquidity and flexibility, supporting a favorable overall outlook.
To see Spark’s full report on COR stock, click here.
More about Cencora
Cencora, Inc. operates in the healthcare industry, focusing on pharmaceutical-centric strategies. It provides healthcare solutions through its U.S. and International Healthcare Solutions segments, offering products and services that cater to market growth, including specialty products and those for diabetes and weight loss.
Average Trading Volume: 1,400,530
Technical Sentiment Signal: Buy
Current Market Cap: $55.89B
Find detailed analytics on COR stock on TipRanks’ Stock Analysis page.